Abdalraheim Mustafa/LinkedIn
Apr 17, 2026, 13:27
Abdalraheim Mustafa: Comparative Analysis of Thrombophilia and Thrombocytosis in Clinical Practice
Abdalraheim Mustafa, Family Medicine Physician at Dr. Sulaiman Al Habib Medical Group, Senior Specialist at World Organization of Family Doctors, shared a post on LinkedIn:
“This is a clear comparison between two diseases, Thrombophilia and Thrombocytosis, which are often confused with each other:
- Thrombophilia
Definition: high tendency to form clots (hypercoagulable state)
Platelets: Normal
Causes:
- Inherited: Factor V Leiden, Protein C/S deficiency
- Acquired: APS, cancer, pregnancy, OCPs
Clinical: DVT, PE, recurrent miscarriage
Diagnosis
- Thrombophilia screen (genetic plus coagulation tests)
- Lupus anticoagulant, anticardiolipin antibodies
Management: Anticoagulation (DOAC / LMWH / warfarin)
- Thrombocytosis
Definition: Platelets more than 450,000/µL
Causes:
- Reactive: infection, inflammation, iron deficiency
- Primary: essential thrombocythemia (MPN)
Clinical: Often asymptomatic, with/without thrombosis or bleeding
Diagnosis
- CBC (high platelets)
- Peripheral smear
- JAK2 mutation testing (if primary suspected)
Management:
- Reactive – treat cause
- Primary – aspirin with/without hydroxyurea
Key Difference
- Thrombophilia – clotting disorder (coagulation factors)
- Thrombocytosis – high platelets
References (Latest Evidence-Based)
- NICE Guidelines (VTE management and thrombophilia testing) 2025.
- ASH Guidelines for VTE and Thrombophilia 2024–2025.
- UpToDate: Thrombophilia and Thrombocytosis (2026 updates).
- WHO Classification of Myeloid Neoplasms 2024.
- Harrison’s Principles of Internal Medicine, 21st Edition.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia
-
Sep 3, 2026, 01:03SHOT Urges Safe Component Matching While NHSBT Appeals for Black Donors
-
Sep 3, 2026, 00:52David Wallace: FDA Approves MIMRYLO to Target Iron Regulation and Reduce Phlebotomy Burden
-
Sep 3, 2026, 00:44Same goal, Different molecular strategy – Which FVIIIa Mimetic Gets There How? – RPTH Journal